uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Low-molecular Weight Heparin Reduces the Generation and Activity of Thrombin in Unstable Coronary Artery Disease
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (Coagulation Research)
Show others and affiliations
1998 (English)In: Thrombosis and Haemostasis, ISSN 0340-6245, Vol. 79, no 3, 491-494 p.Article in journal (Refereed) Published
Abstract [en]

Unstable coronary artery disease (UCAD) is associated with an increased risk of further coronary events. In the FRISC study, the risk was decreased during treatment with a high, twice-daily, dose of dalteparin, a low-molecular-weight heparin. However, lowering the dose resulted in raised risk of recurrences. To investigate the underlying pathophysiology, the thrombin generation and activity in patients with UCAD randomized to a 6-week placebo-controlled treatment with dalteparin were evaluated. Plasma prothrombin fragment 1+2 (F1+2) (n = 342), thrombin-antithrombin complex (TAT) (n = 186) and soluble fibrin (SF) (n = 298) were analyzed before and during treatment with dalteparin/placebo administered subcutaneously, 120 IU/kg bw twice daily for 5-8 days and 7.500 IU once daily the following 35-40 days. High-dose treatment with dalteparin resulted in significantly reduced levels of all coagulation markers, demonstrating diminished thrombin generation and activity. When reducing the dalteparin dose, plasma TAT and SF remained low, indicating minimal fibrin formation. However, F1+2 increased during this period. though the level at day 45 was still lower than in the placebo group. In the placebo group elevated thrombin generation and activity persisted during the entire period. In conclusion, high-dose treatment with dalteparin twice daily resulted in significantly reduced thrombin generation and activity. However, after changing to a lower, once-daily dose, the treatment was not sufficient in preventing a return to a procoagulable state. These changes of the coagulation activity might explain the changes in event rate observed during dalteparin treatment.

Place, publisher, year, edition, pages
1998. Vol. 79, no 3, 491-494 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-55392PubMedID: 9531028OAI: oai:DiVA.org:uu-55392DiVA: diva2:83300
Available from: 2008-10-17 Created: 2008-10-17 Last updated: 2009-12-21Bibliographically approved

Open Access in DiVA

No full text

By organisation
Department of Medical Sciences
In the same journal
Thrombosis and Haemostasis
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 167 hits
ReferencesLink to record
Permanent link

Direct link